Greenwich LifeSciences (NASDAQ:GLSI) Price Target Cut to $38.00

Posted by Defense World Staff on Apr 11th, 2023

Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) had its price objective cut by HC Wainwright from $78.00 to $38.00 in a report published on Monday morning, The Fly reports.

Greenwich LifeSciences Stock Down 3.7 %

NASDAQ:GLSI opened at $12.65 on Monday. Greenwich LifeSciences has a 52 week low of $6.82 and a 52 week high of $21.50. The stock’s fifty day moving average is $15.24 and its two-hundred day moving average is $13.47. The stock has a market capitalization of $162.53 million, a price-to-earnings ratio of -22.19 and a beta of 0.93.

Insider Activity at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 1,500 shares of the business’s stock in a transaction on Friday, January 20th. The shares were bought at an average cost of $17.37 per share, for a total transaction of $26,055.00. Following the completion of the purchase, the chief executive officer now directly owns 2,732,886 shares of the company’s stock, valued at $47,470,229.82. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders bought 7,350 shares of company stock worth $126,633 in the last three months. 52.14% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in Greenwich LifeSciences by 150.2% during the 1st quarter. Vanguard Group Inc. now owns 375,200 shares of the company’s stock worth $7,362,000 after buying an additional 225,213 shares in the last quarter. State Street Corp boosted its holdings in Greenwich LifeSciences by 1.8% in the first quarter. State Street Corp now owns 66,485 shares of the company’s stock valued at $1,304,000 after purchasing an additional 1,176 shares during the period. Bank of America Corp DE grew its stake in Greenwich LifeSciences by 100.2% during the 1st quarter. Bank of America Corp DE now owns 6,213 shares of the company’s stock worth $122,000 after purchasing an additional 3,110 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Greenwich LifeSciences during the 2nd quarter worth about $891,000. Finally, Millennium Management LLC acquired a new stake in Greenwich LifeSciences in the 2nd quarter valued at about $765,000. Institutional investors and hedge funds own 6.18% of the company’s stock.

Greenwich LifeSciences Company Profile

(Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Featured Stories

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.